// App-Quantinova.ai

1867 : Secondary Myelodysplastic Syndrome/Acute Myeloblastic Leukemia During Lenalidomide-Based Regimens in Relapsed and/or Refractory Multiple Myeloma Patients: Single Center Experience

Researchers

Presenter

  • Esther Masih-Khan

Principal Investigators

  • Chia-Min Chu

  • Young Trieu

  • Saima Dean

  • Manjula Maganti

  • Christine I. Chen

  • Vishal Kukreti

  • Suzanne Trudel

  • Donna E. Reece

Medical Centers

  • Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON, Canada

  • McLaughlin Centre for Molecular Medicine, Princess Margaret Hospital, Toronto, ON, Canada

  • Hematology/Oncology, Princess MArgaret Hospital, Toronto, ON, Canada

  • Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Alpha-thalassemia myelodysplasia syndrome

  • Multiple Myeloma

  • Neutropenia

Biomarkers

  • Creatinine

  • Granulocyte colony-stimulating factor

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Lenalidomide

  • Thalidomide

  • Bortezomib

  • Prednisone

  • Melphalan

  • Filgrastim

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved